["[Tab] Consolidated Statements of Earnings from AbbVie Inc.\n\n[Time]: December 31, 2023 [SEP]\n[row 0]: Net revenues $54,318 [SEP] \n[row 1]: Cost of products sold | $20,415 [SEP] \n[row 2]: Selling, general and administrative | $12,872 [SEP] \n[row 3]: Research and development | $7,675 [SEP] \n[row 4]: Acquired IPR&D and milestones | $778 [SEP] \n[row 5]: Other operating expense (income), net | ($179) [SEP] \n[row 6]: Total operating costs and expenses | $41,561 [SEP] \n[row 7]: Operating earnings | $12,757 [SEP] \n[row 8]: Interest expense, net | $1,684 [SEP] \n[row 9]: Net foreign exchange loss | $146 [SEP] \n[row 10]: Other expense, net | $4,677 [SEP] \n[row 11]: Earnings before income tax expense | $6,250 [SEP] \n[row 12]: Income tax expense | $1,377 [SEP] \n[row 13]: Net earnings | $4,873 [SEP] \n[row 14]: Net earnings attributable to noncontrolling interest | $10 [SEP] \n[row 15]: Net earnings attributable to AbbVie Inc. | $4,863 [SEP] \n[row 16]: Basic earnings per share attributable to AbbVie Inc. | $2.73 [SEP] \n[row 17]: Diluted earnings per share attributable to AbbVie Inc. | $2.72 [SEP] \n[row 18]: Weighted-average basic shares outstanding | 1,768 [SEP] \n[row 19]: Weighted-average diluted shares outstanding | 1,773 [SEP] \n\n[Time]: December 31, 2022 [SEP]\n[row 0]: Net revenues $58,054 [SEP] \n[row 1]: Cost of products sold | $17,414 [SEP] \n[row 2]: Selling, general and administrative | $15,260 [SEP] \n[row 3]: Research and development | $6,510 [SEP] \n[row 4]: Acquired IPR&D and milestones | $697 [SEP] \n[row 5]: Other operating expense (income), net | $56 [SEP] \n[row 6]: Total operating costs and expenses | $39,937 [SEP] \n[row 7]: Operating earnings | $18,117 [SEP] \n[row 8]: Interest expense, net | $2,044 [SEP] \n[row 9]: Net foreign exchange loss | $148 [SEP] \n[row 10]: Other expense, net | $2,448 [SEP] \n[row 11]: Earnings before income tax expense | $13,477 [SEP] \n[row 12]: Income tax expense | $1,632 [SEP] \n[row 13]: Net earnings | $11,845 [SEP] \n[row 14]: Net earnings attributable to noncontrolling interest | $9 [SEP] \n[row 15]: Net earnings attributable to AbbVie Inc. | $11,836 [SEP] \n[row 16]: Basic earnings per share attributable to AbbVie Inc. | $6.65 [SEP] \n[row 17]: Diluted earnings per share attributable to AbbVie Inc. | $6.63 [SEP] \n[row 18]: Weighted-average basic shares outstanding | 1,771 [SEP] \n[row 19]: Weighted-average diluted shares outstanding | 1,778 [SEP] \n\n[Time]: December 31, 2021 [SEP]\n[row 0]: Net revenues $56,197 [SEP] \n[row 1]: Cost of products sold | $17,446 [SEP] \n[row 2]: Selling, general and administrative | $12,349 [SEP] \n[row 3]: Research and development | $6,922 [SEP] \n[row 4]: Acquired IPR&D and milestones | $1,124 [SEP] \n[row 5]: Other operating expense (income), net | $432 [SEP] \n[row 6]: Total operating costs and expenses | $38,273 [SEP] \n[row 7]: Operating earnings | $17,924 [SEP] \n[row 8]: Interest expense, net | $2,384 [SEP] \n[row 9]: Net foreign exchange loss | $51 [SEP] \n[row 10]: Other expense, net | $2,500 [SEP] \n[row 11]: Earnings before income tax expense | $12,989 [SEP] \n[row 12]: Income tax expense | $1,440 [SEP] \n[row 13]: Net earnings | $11,549 [SEP] \n[row 14]: Net earnings attributable to noncontrolling interest | $7 [SEP] \n[row 15]: Net earnings attributable to AbbVie Inc. | $11,542 [SEP] \n[row 16]: Basic earnings per share attributable to AbbVie Inc. | $6.48 [SEP] \n[row 17]: Diluted earnings per share attributable to AbbVie Inc. | $6.47 [SEP] \n[row 18]: Weighted-average basic shares outstanding | 1,770 [SEP] \n[row 19]: Weighted-average diluted shares outstanding | 1,777 [SEP]"]